Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
CONCLUSION: Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor-negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.PMID:33999652 | DOI:10.1200/JCO.21.00280
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Roisin M Connolly Jeffrey P Leal Lilja Solnes Chiung-Yu Huang Ashley Carpenter Katy Gaffney Vandana Abramson Lisa A Carey Minetta C Liu Mothaffar Rimawi Jennifer Specht Anna Maria Storniolo Vicente Valero Christos Vaklavas Ian E Krop Eric P Winer Melissa Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | HER2 | Herceptin | Neoadjuvant Therapy | PET Scan | Women